Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation

Digestive and Liver Disease

Volumn 43, Issue 9, 2011, Pages 754-

  Mancuso, Andrea ^a   Airoldi, Aldo ^a   Vigano, Raffaella ^a   Pinzello, Giovambattista ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; SOMATOSTATIN; SORAFENIB; TACROLIMUS; TERLIPRESSIN;

ADULT; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CHEMOEMBOLIZATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; STOMACH HEMORRHAGE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FATAL OUTCOME; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; STOMACH DISEASES;

EID: 79961129711     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.04.022     Document Type: Letter

References (4)

1. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
2. Je Y., Schutz F.A.B., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors aunitinib and sarafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967-974.
3. Bhoori S., Toffanon S., Sposito C., et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010, 52:771-775.
4. Kim R, El-Gazzaz G., Tan A., et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010, 79:62-66.